Photo byNational Cancer InstituteonUnsplash

16 May 11:00-12:00Glasburen KBC-huset

Photo byNational Cancer InstituteonUnsplash

Transforming Rare Disease Research

Founded over 60 years ago by parents of children battling rare diseases, AFM-Téléthon is a driving force in advancing scientific research and innovative treatments, emphasizing neuromuscular disorders.

Treatments and therapeutic innovation are born out of the knowledge of genes and the understanding of the mechanisms causing disease. Beyond its three pioneering laboratories combined within the Biotherapies Institute for rare diseases, AFM-Téléthon has been developing collaborations for many years with scientists from all over the world

In the seminar on May 16th, Jean-François Briand, PhD, Deputy Scientific Director at AFM-Téléthon, will speak on how a patient association can develop a pipeline of innovative therapies from bench to industrialization.

Learn more at the AMF-Téléthon website

Speakers

Jean-François Briand
Deputy Scientific Director, PhD

Jean-François has worked 14 years for AMF Telethon and has a background in translational research, from the first ideas to preclinical and clinical development. Experience covers areas such as the production of recombinant proteins, therapeutic molecules in fungal infections, and the development of innovative therapies such as gene and cell therapy.

Read more

State aid 

Participation fee: This event is sponsored by Umeå Biotech Incubator (UBI) with support from the European Union. There is no actual fee for participating. For delegates from the industry, state-aid/de-minimis will be accounted for corresponding to 300 SEK per person.

State aid & de-minimis: Umeå Biotech Incubator is obliged to account for activities they arrange, and support they provide, directed to specific companies or a group of companies where the receiving companies do not pay market price for the participation. The value of this support is accounted for as state-aid. 

Small amounts of State aid (‘de minimis’ aid) are exempted from State aid control, as they are deemed to have no impact on competition and trade in the internal market of the European Union (EU). 

De minimis aid indeed refers to small amounts of State aid to undertakings (companies) that do not have to be notified to the European Commission by the EU Member States. The maximum amount is € 300,000 for each undertaking over 3 years.

De minimis can also be granted to large companies that are not entitled to larger sums of state-aid under Article 22. Read more on state-aid and de-minimis here:

© MapTiler © OpenStreetMap contributors

Organized by